Table 3.
Comparison of clinical and laboratory data in patients with and without C4d deposition in different renal compartments.
| Glomeruli | Arteriole | PTC | TBM | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0/1+43pt | 2+/3+282pt | P | Negative 223pt | Positive 102pt | P | Negative 215pt | Positive 110pt | P | Negative 183pt | Positive 142pt | P | |
| Gender (male/female) | 8/35 | 46/236 | 0.707 | 40/183 | 14/88 | 0.423 | 40/175 | 14/96 | 0.209 | 34/149 | 20/122 | 0.297 |
| Age (year) (mean±s.d.) | 33.81±12.62 | 32.59±11.38 | 0.665 | 32.43±11.42 | 33.46±11.83 | 0.456 | 31.90±11.47 | 34.43±11.55 | 0.061 | 32.38±11.10 | 33.23±12.10 | 0.511 |
| Number with hematuria (%) | 36 (83.7%) |
213 (75.5%) |
0.238 | 171 (76.7%) |
78 (76.5%) |
1.000 | 160 (74.4%) |
89 (80.9%) |
0.214 | 132 (72.1%) |
117 (82.4%) |
0.035 |
| Numbers with leukocyturia (non-infectious) (%) | 23 (53.5%) |
150 (53.2%) |
0.990 | 117 (52.5%) |
56 (54.9%) |
0.721 | 115 (53.5%) |
58 (52.7%) |
0.907 | 83 (45.4%) |
90 (63.4%) |
0.002 |
| Urine protein (g/24h) (median, IQR) | 3.34 (1.61-4.88) |
4.45 (2.38-7.00) |
0.031 | 4.30 (2.04-6.82) |
4.34 (2.75-6.90) |
0.238 | 4.26 (2.04-6.39) |
4.46 (2.77-8.00) |
0.084 | 4.00 (1.87-6.30) |
4.84 (2.86-7.62) |
0.004 |
| Numbers with acute kidney injury (%) | 9 (20.9%) |
56 (19.9%) |
0.870 | 41 (18.4%) |
24 (23.5%) |
0.298 | 41 (19.1%) |
24 (21.8%) |
0.561 | 25 (13.7%) |
40 (28.2%) |
0.001 |
| Serum creatinine (μmmol/l) (median, IQR) | 84 (68-157) | 82 (68-131) | 0.550 | 79 (66-115) | 92 (73-189) | 0.002 | 80 (66-119) | 87 (72-169) | 0.014 | 78 (65-98) | 99 (73-187) | <0.001 |
| C3 (g/L) (median, IQR) | 0.35 (0.19-0.48) |
0.44 (0.34-0.63) |
<0.001 | 0.42 (0.29-0.62) | 0.44 (0.33-0.63) | 0.528 | 0.45 (0.32-0.65) | 0.41 (0.30-0.51) | 0.036 | 0.46 (0.33-0.65) |
0.41 (0.28-0.56) |
0.014 |
| C4 (g/L) (median, IQR)# | 33 patients 0.04 (0.025-0.125) |
206 patients 0.11 (0.05-0.17) |
0.001 | 176 patients 0.095 (0.033-0.16) |
63 patients 0.12 (0.08-0.17) |
0.027 | 162 patients 0.11 (0.04-0.17) |
77 patients 0.10 (0.05-0.15) |
0.442 | 135 patients 0.10 (0.03-0.17) |
104 patients 0.11 (0.06-0.15) |
0.481 |
| Numbers with ANA Positivity (%) | 43 (100%) |
277 (98.2%) |
0.380 | 220 (98.7%) |
100 (98.0%) |
0.651 | 211 (98.1%) |
109 (99.1%) |
0.666 | 179 (97.8%) |
141 (99.3%) |
0.391 |
| Numbers with positive Anti-dsDNA Ab (%) | 35 (81.4%) |
178 (63.1%) |
0.022 | 149 (66.8%) |
64 (62.7%) |
0.528 | 136 (63.3%) |
77 (70.0%) |
0.217 | 115 (62.8%) |
98 (69.0%) |
0.240 |
| Numbers with positive aCL (%)## | 2/24 (8.3%) |
17/174 (9.8%) |
0.823 | 17/139 (12.2%) |
2/59 (3.3%) |
0.054 | 11/131 (8.4%) |
8/67 (11.9%) |
0.424 | 11/109 (10.1%) |
8/89 (9.0%) |
0.794 |
| SLEDAI (median, IQR) | 18 (15-23) | 17 (13-21) | 0.172 | 17 (13-21) | 17 (13-21) | 0.882 | 17 (13-20) | 18 (14-22) | 0.096 | 16 (12-20) | 18 (15-22) | 0.001 |
Glomeruli was divided into 0/1+ and 2+/3+ subgroups according to the glomerular C4d intensity; Arteriolar, PTC and TBM was divided into negative and positive subgroups according to the C4d positivity. Pt, patients; PTC, peritubular capillary; TBM, tubular basement membrane; ANA, antinuclear antibody; Anti-dsDNA Ab, Anti-double-stranded DNA antibody; aCL, anti-cardiolipin antibody; SLEDAI, systemic lupus erythematosus disease activity index. #C4 was analyzed based on the data of 239 patients with C4 level tested at the onset of the disease; ##aCL was analyzed based on the data of 198 patients with aCL level tested at the onset of the disease.